Cabaletta Bio (CABA) Stock: Buy, Sell, or Hold?
CABA - Cabaletta Bio, Inc. Common Stock
$2.73
-0.01 (-0.36%)
▼
5d:
-21.55%
30d:
-4.21%
90d:
-9.3%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When CABA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CABA is down 21.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CABA is down 21.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CABA is currently trading at $2.73, which is considered oversold relative to its 30-day fair value range of $2.75 to $3.28.
Technical Outlook: Technically, CABA is in a downtrend. The price is currently testing key support at $2.67. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CABA scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.25 (+385.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CABA is in a downtrend. The price is currently testing key support at $2.67. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CABA scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.25 (+385.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.75 -
$3.28
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (29/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 385.3% below Wall St target ($13.25)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.75 -
$3.28
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.67
Resistance Level
$3.75
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.85
Wall Street Target
$13.25
(+385.3%)
Share & Embed Analysis
Last updated: September 12, 2026 9:05 AM ET
Data refreshes hourly during market hours. Next update: 10:05 AM
Data refreshes hourly during market hours. Next update: 10:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CABA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
